Immune Responses to Dengue and Sepsis

Launched by INSTITUT PASTEUR DU CAMBODGE · Jun 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the immune system responds to two serious illnesses: dengue fever and sepsis, which is a severe infection. The researchers want to learn more about how these diseases affect the body by collecting health information and taking up to four blood samples from people with dengue, people with sepsis, and healthy volunteers. By comparing these results, they hope to better understand the differences and similarities in the immune responses between these groups.

People who may join the study include those who have recently developed symptoms that look like dengue fever (such as a high fever, headache, muscle or joint pain, rash, or nausea) within the last three days, patients who have been recently admitted to the hospital with sepsis, and healthy individuals without any recent infections or ongoing health problems. If you join, you can expect to provide some health information and give a few blood samples over time. The study excludes young children under 2 years old, pregnant or breastfeeding women, and people with certain long-term health conditions or those taking specific medications. Participation is voluntary, and the researchers will explain everything before you decide.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients with dengue-like illness:
• • Patients presenting with dengue-like symptoms for a duration of maximum 72h before inclusion. Dengue-like symptoms include: presentation with oral temperature \>38°C AND at least two of the following symptoms suggestive of dengue-like illness: headache, retro-orbital pain, myalgia, joint pain, rash, any bleeding symptoms, nausea or vomiting, lethargy or restlessness , abdominal pain, liver enlargement
• * Sepsis patients:
• • Patients admitted for less than 48 hours with a primary diagnosis of sepsis as per treating team AND have blood cultures ordered AND on empiric antibiotics due to concern for bacterial infection.
• * Healthy controls:
• • Participants with no chronic illness, no regular medications, no febrile illness in 28 days, no diagnosis of or treatment for dengue or bacterial infection in the past 6 months.
• Exclusion Criteria:
• • For biobanking purposes, children less than 2 years of age, and individuals who are pregnant, pregnant within the last 90 days, and/or breastfeeding are excluded due to restrictions on the blood volumes and the repeated sampling times.
• • Individuals that do not provide informed consent will not be included for the study.
• • Severe/chronic/recurrent pathological conditions: clinically significant autoimmune disease or immunodeficiency (including history of organ transplant), haematologic disorders, cardiac diseases, diabetes, cancer, HIV, chronic hepatic or renal insufficiency.
• • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months prior to the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg/day of prednisone or equivalent for \> 2 weeks (inhaled and topical steroids allowed)
• • Chronic administration of NSAIDs, including aspirin: prolonged intake (\>2 weeks) within 6 months before study or any intake within the 7 days preceding sampling \[exception for low dose aspirin: maximum 250mg/daily\]
• • Any underlying, chronic, or current condition that, in the opinion of the investigator, may interfere with their participation in the study.
• • Expected death in the next 48-hours